Researchers sought to determine if vagal nerve activity could predict overall survival and progression-free survival in patients with R/R DLBCL and MM, respectively.
A case report describes an atypical presentation of multiple myeloma marked by immunogammopathy maculopathy and hyperviscosity syndrome-related retinopathy.
Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.
Multiple myeloma is an uncommon form of cancer, and one that may not produce symptoms right away. Because of this, patients with higher risk due to family history, exposure, or other reasons may need more education about it. How can you explain multiple myeloma to your patients?
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
For patients with relapsed or refractory multiple myeloma, subcutaneous bortezomib may improve the tolerability of combination panobinostat, bortezomib, and dexamethasone.
Intermittent dosing of the targeted agent may overcome toxicity limitations, providing a potential therapy for a hard-to-treat multiple myeloma.
An analysis of outcomes for older patients with plasma cell myeloma suggests lenalidomide with bortezomib and dexamethasone is superior to doublet regimens.
The inclusion of daratumumab in multiple myeloma regimens may be linked to better progression-free survival.
Multiple myeloma trials appear to underrepresent racial minorities in enrollment and in reporting, with no obvious improvement in recent years.
